van Zandwijk et al., 1989 - Google Patents
Dose-Finding Studies with Carboplatin, Ifosfamide, Etoposide and Mesna in Non-Small Cell Lung Cancervan Zandwijk et al., 1989
- Document ID
- 17800567609110144576
- Author
- van Zandwijk N
- ten Bokkel Huinink W
- Wanders J
- Simonetti G
- Dubbelman R
- Franklin H
- Brouwer M
- McVie J
- Publication year
- Publication venue
- Ifosfamide in the Treatment of Lung Cancer
External Links
Snippet
Hossfeld DK (ed): Ifosfamide in the Treatment of Lung Cancer. Contrib Oncol. Basel, Karger,
1989, vol 35, pp 119-121. Dose-Findi Page 1 Hossfeld DK (ed): Ifosfamide in the Treatment of
Lung Cancer. Contrib Oncol. Basel, Karger, 1989, vol 35, pp 119-121. Dose-Finding Studies …
- 229960004562 Carboplatin 0 title abstract description 15
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/30—Copper compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/36—Arsenic; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Loehrer Sr et al. | VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory germ cell cancer. | |
| NO315027B1 (en) | Antitumor preparations containing taxane derivatives | |
| US8927530B2 (en) | Therapeutic combination comprising a PLK1 inhibitor and an antineoplastic agent | |
| RU2284184C2 (en) | Method for treating cancer | |
| US6699844B2 (en) | Methods for treating cellular proliferative disorders | |
| SK16392002A3 (en) | Combination chemotherapy | |
| EP2254570B1 (en) | Combination comprising paclitaxel for treating ovarian cancer | |
| Kok et al. | Cisplatin and etoposide in oesophageal cancer: a phase II study | |
| Sessa et al. | Gemcitabine in patients with advanced malignant melanoma or gastric cancer: phase II studies of the EORTC Early Clinical Trials Group | |
| Plaxe et al. | Phase I and pharmacokinetic study of intraperitoneal topotecan | |
| Cascinu et al. | A phase I study of paclitaxel and 5-fluorouracil in advanced gastric cancer | |
| van Zandwijk et al. | Dose-Finding Studies with Carboplatin, Ifosfamide, Etoposide and Mesna in Non-Small Cell Lung Cancer | |
| Rougier | Docetaxel delivers new management opportunities for gastrointestinal carcinomas | |
| Pronzato et al. | Carboplatin and vinorelbine in advanced non-small-cell lung cancer | |
| Smith et al. | Evaluation of topotecan in patients with recurrent for metastatic squamous cell carcinoma of the head and neck: A phase II Southwest Oncology Group study | |
| Sands et al. | Preclinical activity of an iv formulation of rubitecan in IDD-P™ against human solid tumor xenografts | |
| Gasparini et al. | Continuous cisplatin infusion in combination with vincristine and high-dose methotrexate for advanced osteogenic sarcoma | |
| Creasey et al. | Action of (S)-10-Hydroxycamptothecin on P388 Leukemia and Distribution of the Drug in Mice¹, 2 | |
| Schilsky et al. | Phase I Clinical Evaluation of Cytarabine and Cisplatin in Patients With Advanced Cancer¹ | |
| US20180207173A1 (en) | Administration of aurora kinase inhibitor and chemotherapeutic agents | |
| Relias et al. | Topoisomerase I inhibitors: 1. Topotecan | |
| Gatzemeier et al. | Phase II study with paclitaxel in advanced inoperable non-small cell lung cancer (NSCLC)—the European experience | |
| Rosell et al. | Ifosfamide in non-small-cell lung cancer | |
| Di Costanzo et al. | Cisplatin and Low-Dose Cytosine Arabinoside in Advanced Cancer | |
| Vansteenkiste et al. | Vindesine-ifosfamide-platinum (VIP) chemotherapy in patients with stage III and IV non small cell lung cancer. A phase II trial |